Osmo-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric stasis. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these agents in Osmo-DSR Capsule offers symptomatic relief and promotes mucosal healing by reducing acid load and enhancing gastrointestinal motility. This combination is particularly beneficial in patients with delayed gastric emptying accompanied by acid-related symptoms. Osmo-DSR should be administered as prescribed by a healthcare professional, typically once daily before meals. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Common adverse effects may include headache, dry mouth, abdominal cramps, and dizziness. Consultation with a healthcare provider is recommended prior to use to ensure suitability and monitor for potential drug interactions.